GlassScriptPhysician profile
Caroline B Mcculley
NPI 1558709089
$3,641.52
in general payments reported to CMS, 2019-2025
21 companies · $19.30 in 2025
The $19.30 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,435 · 2020: $119 · 2021: $235 · 2023: $1,833 · 2025: $19.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,620 · Food and Beverage: $143 · Education: $89.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,620.00 |
| Food and Beverage | $143.06 |
| Education | $89.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,912.08 | 2019-2023 | Tremfya |
| Amgen INC. | $443.38 | 2019-2021 | |
| Abbvie INC. | $240.32 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $198.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $163.81 | 2019 | |
| Pfizer INC. | $115.64 | 2019-2021 | |
| Genentech USA, INC. | $80.25 | 2019 | |
| Genzyme Corporation | $74.44 | 2020-2021 | |
| Glaxosmithkline, LLC. | $73.21 | 2019-2020 | |
| Horizon Therapeutics Plc | $71.67 | 2019-2020 | |
| Lilly USA, LLC | $47.54 | 2019-2021 | |
| Ucb, INC. | $36.59 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.21 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.82 | 2019 | |
| Pacira Therapeutics, INC. | $23.18 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $22.13 | 2019 | |
| Celgene Corporation | $19.37 | 2019 | |
| Radius Health, INC. | $18.60 | 2019 | |
| Antares Pharma, INC. | $16.40 | 2019 | |
| Merck Sharp & Dohme LLC | $14.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Mcculley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.